The tumor‐suppressive effects of adiponectin are largely mediated through its receptors, adiponectin receptor 1 and adiponectin receptor 2 (AdipoR1 and AdipoR2), which activate key pathways, including AMPK and Peroxisome proliferator‐activated receptor alpha (PPAR‐α). This evidence concerns the gene ADIPOQ and neoplasm.